Literature DB >> 11752035

Contribution of volume overload and angiotensin II to the increased pulse wave velocity of hemodialysis patients.

J L Tycho Vuurmans1, Walther H Boer1, Willem-Jan W Bos1, Peter J Blankestijn1, Hein A Koomans1.   

Abstract

Aortic compliance is decreased in patients with end-stage renal disease. This malfunction contributes to high aortic systolic pressures and thus to the development of left ventricular hypertrophy. It was hypothesized that besides structural vascular changes, functional changes as a result of hypervolemia and increased vasoconstrictor activity, in particular angiotensin II, play a role in decreasing aortic compliance. Nineteen hemodialysis patients were studied before and 24 h after they had been dialyzed to dry weight. Applanation tonometry of peripheral arteries was used to estimate aortic pulse wave velocity (PWV), known to depend on aortic compliance, and aortic systolic pressure augmentation (augmentation index [Aix]). Predialysis aortic PWV was increased in the dialysis patients compared with matched healthy subjects (9.9 +/- 3.1 versus 7.5 +/- 1.1 m/s; P < 0.05). The AIx was also increased (35 +/- 6 versus 25 +/- 10; P < 0.05). Volume reduction with dialysis had no significant effect on PWV (9.3 +/- 1.5 m/s), but the AIx decreased (28 +/- 7; P < 0.05). A subset of 10 patients were restudied after 1 wk of angiotensin-converting enzyme inhibition (ACEi) with enalapril 5 mg once daily. ACEi decreased both predialysis as postdialysis BP but had no effect on pulse pressure and heart rate, which remained elevated compared with healthy subjects. ACEi also decreased predialysis aortic PWV, from 11.0 +/- 3.5 to 9.1 +/- 2.1 m/s (P < 0.05) but had no significant effect on AIx. During treatment with ACEi, the same volume reduction with dialysis decreased aortic PWV further to 8.0 +/- 1.4 m/s (P < 0.05), a figure not different from PWV in healthy subjects. AIx decreased to an even slightly subnormal value (12 +/- 23; P < 0.05). It was concluded that volume overload and angiotensin II both contribute to elevated PWV and AIx in dialysis patients. Volume reduction and ACEi both improve the aortic PWV and AIx. Combined volume reduction and ACEi has an enhanced effect that, in the present patients, was so large that PWV and AIx were no longer elevated. Monitoring and correcting of arterial pressure waves is feasible and may be an important tool in the treatment of patients with end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11752035     DOI: 10.1681/ASN.V131177

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  22 in total

1.  Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis.

Authors:  Tara I Chang; David Shilane; Steven M Brunelli; Alfred K Cheung; Glenn M Chertow; Wolfgang C Winkelmayer
Journal:  Am Heart J       Date:  2011-07-18       Impact factor: 4.749

2.  The association between arterial stiffness and fluid status in peritoneal dialysis patients.

Authors:  Ismail Kocyigit; Murat Hayri Sipahioglu; Ozcan Orscelik; Aydin Unal; Ahmet Celik; Samer R Abbas; Fansan Zhu; Bulent Tokgoz; Ali Dogan; Oktay Oymak; Peter Kotanko; Nathan W Levin
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

3.  Changes in pulse pressure during hemodialysis treatment and survival in maintenance dialysis patients.

Authors:  Paungpaga Lertdumrongluk; Elani Streja; Connie M Rhee; John J Sim; Daniel Gillen; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-01       Impact factor: 8.237

4.  Ambulatory recording of wave reflections and arterial stiffness during intra- and interdialytic periods in patients treated with dialysis.

Authors:  Antonios Karpetas; Pantelis A Sarafidis; Panagiotis I Georgianos; Athanase Protogerou; Pantelis Vakianis; Georgios Koutroumpas; Vasileios Raptis; Dimitrios N Stamatiadis; Christos Syrganis; Vassilios Liakopoulos; Georgios Efstratiadis; Anastasios N Lasaridis
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-29       Impact factor: 8.237

5.  Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial.

Authors:  Philip Kam-Tao Li; Yuk Lun Cheng; Chi Bon Leung; Cheuk Chun Szeto; Kai Ming Chow; Bonnie Ching-Ha Kwan; Esther Siu-Chun Ng; Queenie Wing-Yi Fok; Yuet Ling Poon; Alex Wai-Yin Yu
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

6.  Interdialytic weight gain and vasculopathy in children on hemodialysis: a single center study.

Authors:  Vasiliki Karava; Cherine Benzouid; Theresa Kwon; Marie-Alice Macher; Georges Deschênes; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2018-09-03       Impact factor: 3.714

7.  Effects of hemodialysis on the cardiovascular system: quantitative analysis using wave intensity wall analysis and tissue velocity imaging.

Authors:  Anna Bjällmark; Matilda Larsson; Jacek Nowak; Britta Lind; Shirley Yumi Hayashi; Marcelo Mazza do Nascimento; Miguel C Riella; Astrid Seeberger; Lars-Åke Brodin
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

Review 8.  Arterial stiffness in dialysis patients: where are we now?

Authors:  Mehmet Kanbay; Baris Afsar; Paul Gusbeth-Tatomir; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2009-11-19       Impact factor: 2.370

Review 9.  Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis.

Authors:  Madhavi Mallareddy; Chirag R Parikh; Aldo J Peixoto
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-06       Impact factor: 3.738

10.  Change in Pulse Wave Velocity and Short-Term Development of Cardiovascular Events in the Hemodialysis Population.

Authors:  Serge Korjian; Yazan Daaboul; Balsam El-Ghoul; Salam Samad; Pascale Salameh; Georges Dahdah; Essa Hariri; Anthony Mansour; Kathryn Spielman; Jacques Blacher; Michel E Safar; Sola Aoun Bahous
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-05-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.